FDA compounding committee, July 2026: seven research peptides on the agenda

Prepared by: Research Desk. Sources are linked for verification.

Published 21 October 2026

What FDA has announced

The US Food and Drug Administration (FDA) has published a meeting page for a two-day meeting of its Pharmacy Compounding Advisory Committee on 23 and 24 July 2026. According to that page, the committee will discuss seven peptide-related bulk drug substances "being considered for inclusion on the 503A Bulks List".

This article summarises the agenda, the uses FDA states it reviewed, the docket details and the context of FDA's category 2 list.

This page does not report the committee's votes or FDA's final decisions. Any outcome, and any later regulatory action, should be checked directly on the FDA meeting page and related FDA records.

Day one: 23 July 2026

The agenda lists four substance groups for the first day, each named in a free base and an acetate form. The meeting page includes a chart that, in FDA's words, "identifies the use(s) FDA reviewed for each of the bulk drug substances being discussed".

These entries record the scope of FDA's review of each nomination. They are not a statement that any substance has been shown to work for the conditions listed.

Day two: 24 July 2026

Three substance groups are listed for the second day, again each in free base and acetate forms. FDA notes that emideltide is "also referred to as delta sleeping inducing peptide (DSIP)".

Nominator presentations and meeting materials

For both days, the page states that "the nominators of these substances will be invited to make a short presentation supporting the nomination".

FDA says it intends to post background material and a link to the live webcast "no later than two (2) business days before the meeting" in the Event Materials section of the page. If that is not possible, the material will be made available at the meeting location and on FDA's website at the time of the meeting. The background documents, once posted, are where FDA's own assessment of each substance will appear. This article does not summarise them.

Public docket

According to the meeting page, FDA has established a docket for public comment:

• Docket number: FDA-2025-N-6895
• Closing date: 22 July 2026

The page states that interested persons may present data, information or views, orally or in writing, on issues pending before the committee. It also notes that late or untimely comments are handled differently; the exact terms are on the FDA page.

Context: the category 2 list

Separately, FDA maintains a page on bulk drug substances used in compounding that may present significant safety risks. FDA explains there that it identified potential significant safety risks when reviewing nominations for the 503A or 503B bulks lists, and that such substances "have been placed in category 2 under the interim policies".

That page also lists substances previously in category 2 whose nominations were withdrawn by the nominators. BPC-157 appears in that section. FDA's stated concerns were that compounded drugs containing it "may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization", and that the agency "lacks sufficient information to know whether the drug would cause harm when administered to humans". The same withdrawn section lists thymosin beta-4 fragment (LKKTETQ), also known as TB-500.

FDA's category 2 page also lists emideltide (DSIP), which is on the 24 July agenda. This article does not state which part of that page the entry sits in; the current wording and status should be checked on the FDA page itself.

The meeting page does not describe how the July 2026 review relates to these earlier category 2 entries. Readers interested in that connection should consult FDA's records directly rather than infer an outcome.

What the record does and does not show

The meeting page establishes the dates, the seven substance groups, the salt forms named, the uses FDA reviewed, the invitation to nominators and the docket details. It does not indicate how the committee will advise FDA, what FDA will decide, or how strong the scientific evidence for any listed use is.

For several of these substances the published research base is limited. Much of the BPC-157 literature comes from rat studies by a single research group, published work on TB-500 as a distinct compound is largely analytical chemistry for doping control, and human studies of MOTs-C are mostly observational. A listed "use evaluated" reflects the scope of a regulatory review, not an established finding.

For a general approach to regulatory items like this one, see our guide on how to read a research signal. For a contrasting example, see our report on elamipretide's accelerated approval: a peptide that received FDA accelerated approval for one rare disease, based on an intermediate endpoint and conditional on a confirmatory trial.

Where to check for updates

The authoritative source for the agenda, materials, any change of schedule and the meeting outcome is the FDA meeting page. Public comments are filed under docket FDA-2025-N-6895.

Supplier

Purita is a store that sells peptides for laboratory research use only, and its product pages label items for research use only and not for human or animal administration.

Visit the Purita website

Affiliate disclosure: this is a paid link. KlowSignal earns a commission if a purchase is made through it, at no extra cost to the buyer. A listing is not an endorsement or a statement about product quality. See the affiliate disclosure.

Related pages

• Research peptide signals: studies and regulatory updates
• About KlowSignal
• How to read a research or regulatory signal
• Elamipretide (SS-31): the 2025 accelerated approval on the record